Delic Holdings Corp. Stocks

CA$ 0Last Updated 23.03.2026

Issuer Rating

Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

CA$ 320728.5606

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CA$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Delic Holdings Corp. provides various medicines and treatments in the United States and Canada. It operates The Delic, a creative platform that creates and hosts public discourse about psychedelic culture; Meet Delic, which organizes event to promote topics, such as safety and harm reduction, Hollywood, mental health and psychedelics, the power of integration, human performance, medicine, and other topics; Reality Sandwich, a public online education platform with approximately 10,000 pieces of content, including psychedelic guides, news, and culture; and Delic Radio, a podcast that discusses topics related to the psychedelic space with experts comprising discussions relating to news, science, culture, medicine, current affairs, and policy. The company also focuses on developing intellectual property through research and development for cannabis and psychedelics. In addition, it owns and operates two ketamine infusion treatment clinics; and thirteen ketamine infusion treatment clinics. The company is headquartered in Vancouver, Canada.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks